Scarica l'app Stockscreener
24.42
3.52%
0.83
Dopo l'orario di chiusura:
24.90
0.48
+1.97%
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
How to use a screener to detect IDEAYA Biosciences Inc. breakoutsBuy Strategy Tracker with Growth Indicators - Newser
Analyzing net buyer seller activity in IDEAYA Biosciences Inc.Ten-Year Sector Performance and Summary Analysis - Newser
How sentiment analysis helps forecast IDEAYA Biosciences Inc.Risk Shielded Trade Watch with Analysis - Newser
Leerink Partnrs Has Bullish Estimate for IDYA Q3 Earnings - Defense World
Has IDEAYA Biosciences Inc. found a price floorFree Entry Zone Strategy for Consistent Profit - Newser
Cantor Fitzgerald Issues Negative Forecast for IDYA Earnings - Defense World
Will IDEAYA Biosciences Inc. outperform the marketLow Volatility Stock Analysis With Confidence - Newser
Is a relief rally coming for IDEAYA Biosciences Inc. holdersTen-Year Sector Performance and Summary Analysis - Newser
GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer? - TipRanks
IDEAYA Biosciences: Hold Rating Amid Key Pipeline Developments and Anticipated Clinical Milestones - TipRanks
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $48.09 Average PT from Analysts - Defense World
Wedbush Predicts Increased Earnings for IDEAYA Biosciences - Defense World
RBC Capital Remains a Buy on IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences Reports Q2 2025 Financial Results - The Globe and Mail
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025 - MSN
Risk vs reward if holding onto IDEAYA Biosciences Inc.Free Early Breakout Entry Point Notifications - Newser
IDEAYA Biosciences Inc Reports Q2 2025 Financial Results: Net Loss of $77.5 Million, EPS of -$0.88, and No Revenue - AInvest
Ideaya Biosciences Q2 EPS Beats Consensus, Sees Catalyst-Rich Period Ahead - AInvest
GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959 - TipRanks
Chart based analysis of IDEAYA Biosciences Inc. trendsPredictive Model for Intraday Swing Forecast - Newser
Ideaya Biosciences shares rise 3.19% premarket after reporting Q2 net loss and positive trial data. - AInvest
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
IDEAYA (IDYA) Q2 Net Loss Improves 27% - The Motley Fool
IDEAYA (IDYA) Q2 Net Loss Improves 27% - Nasdaq
IDEAYA Biosciences Reports Q2 Net Loss of $0.88 - MarketScreener
IDEAYA Biosciences Enters ADC Market with Solid Tumor Focus - AInvest
IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA) - Seeking Alpha
Ideaya Biosciences earnings missed by $0.09, revenue topped estimates - Investing.com
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IDEAYA Biosciences Reports Q2 GAAP EPS of -$0.88, Misses Expectations - AInvest
IDEAYA Biosciences's Q2 net loss widens as costs mount - MarketScreener
IDEAYA Reports Phase 2/3 Trial Data and Neoadjuvant Darovasertib Results - AInvest
IDEAYA Advances 6 Clinical Programs, Reports Massive $992M Cash Runway Through 2029 - Stock Titan
Pliant Therapeutics shares rise 2.65% intraday after IDEAYA Biosciences reports positive Phase 2/3 trial data. - AInvest
Published on: 2025-08-05 04:17:11 - metal.it
Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study - TipRanks
Ideaya Biosciences shares rise 6.02% premarket as New Zealand shares down tracking Wall Street sell-off. - AInvest
What institutional investors are buying IDEAYA Biosciences Inc. stockCapitalize on proven trading setups - Jammu Links News
How many analysts rate IDEAYA Biosciences Inc. as a “Buy”Maximize portfolio growth with expert advice - Jammu Links News
How does IDEAYA Biosciences Inc. compare to its industry peersConsistent triple-digit returns - Jammu Links News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - cnhinews.com
What analysts say about IDEAYA Biosciences Inc. stockGet expert advice on portfolio optimization - Jammu Links News
Should I hold or sell IDEAYA Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
What makes IDEAYA Biosciences Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
What drives IDEAYA Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the risk reward ratio of investing in IDEAYA Biosciences Inc. stockGet alerts on the hottest stocks daily - Jammu Links News
How strong is IDEAYA Biosciences Inc. company’s balance sheetMarket-crushing stock picks - Jammu Links News
What catalysts could drive IDEAYA Biosciences Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
IDEAYA Biosciences Awards Stock Options to New Employee - AInvest
Historical volatility pattern of IDEAYA Biosciences Inc. visualizedIntraday Signal Forecast for Fast Traders - Newser
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
IDEAYA Biosciences Awards $765K Worth of Stock Options to New Employee: Full Grant Details - Stock Titan
How to build a custom watchlist for IDEAYA Biosciences Inc.Consistent Gain Plan with AI Support - Newser
TD Cowen Bullish on Ideaya’s (IDYA) Oncology Pipeline - MSN
What is IDEAYA Biosciences Inc. company’s growth strategyPost Market Review For 2025 - jammulinksnews.com
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):